formutech Summit

Sponsors 2026

25+ Speakers | 80+ Industry Leaders | 10 Exclusive Sponsors

"The prestigious conference
on mRNA development |
LNP Formulations

FormuTech Summit Sponsors 2026

Diamond Sponsors

Unchained labs

Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing AI-native automation and purpose-built analytical tools designed for the AI-driven lab. That’s our mantra, our promise, and we own it.

VISIT WEBSITE

Sartorius

Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius’ advanced therapy solutions are designed to overcome current ATMP production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company’s continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.

VISIT WEBSITE

gold Sponsors

leon-nanodrugs

leon-nanodrugs GmbH specializes in the development of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). The company leverages its proprietary FR-JET® technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and large-scale commercial production. LEON’s platform solves scale-up unpredictability: consistent mixing from lab to GMP scale cuts re-optimization and CMC disruption risk – the real cost isn’t lost materials, it’s lost time to process lock, clinical milestones, and ultimately product NPV.

VISIT WEBSITE

Silver Sponsors

4basesbio

4basebio is a Cambridge-based biotechnology company and GMP-certified manufacturer of synthetic DNA, advancing next-generation therapeutics and vaccines with fast, flexible, and high-purity synthetic nucleic acid solutions. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces application-specific synthetic DNA designed to overcome the limitations of conventional plasmid-based systems.

4basebio’s clinically validated opDNA® construct is optimised for mRNA production, eliminating the need for enzymatic linearisation and enabling dose reductions with increased purity and consistency compared with plasmid DNA. These solutions help partners accelerate proof-of-concept studies and progress towards clinical milestones more efficiently, while maintaining the highest standards of safety and quality.

With a focus on innovation, flexibility, and precision, 4basebio equips biopharma and academic partners with the tools to unlock the full potential of genetic medicine.

VISIT WEBSITE

eXmoor Pharma

eXmoor Pharma is a full-service Cell & Gene Therapy CDMO with a difference. Founded in 2004 and backed by more than 20 years of consultancy experience, eXmoor has supported over 190 organisations in accelerating therapies from discovery to delivery.
eXmoor combines strategic CMC consultancy, process development, analytical services and GMP manufacturing to provide comprehensive support across Viral Vectors, Autologous and Allogeneic Cell Therapies, and RNA technologies. This integrated model enables seamless progression from early-phase strategy through to commercial readiness.
Its purpose-built GMP facility includes four Grade C cleanrooms, a dedicated Fill Finish suite, in-house QC labs and on-site Qualified Persons. With MHRA approval for clinical manufacturing and a global reach, eXmoor is trusted by clients at all stages of development and commercialisation.
Unlike many CDMOs, eXmoor does not retain client IP. Clients maintain full control over their innovations while benefiting from flexible partnership, transparency and continuity across teams. eXmoor provides the support and freedom innovators need to focus on what matters most: getting life-changing treatments to patients faster.

VISIT WEBSITE

Cytiva

Cytiva enables the development and manufacture of advanced therapies through technologies and expertise on cell therapy, viral vectors, nucleic acid therapeutics, and nanomedicine.

With leading capabilities in nanomedicine, Cytiva supports innovators developing lipid nanoparticle (LNP)-enabled therapies, helping accelerate the delivery of RNA-based and other next-generation medicines to patients.

VISIT WEBSITE

Event partners

SPARTA Biodiscovery

Single‑particle analytics with SPARTA® provides a level of resolution that conventional ensemble methods cannot achieve. By characterizing individual nanoparticles in terms of drug loading, lipid or polymer composition, and surface functionalization, SPARTA® exposes particle‑to‑particle heterogeneity and distinct sub‑populations that are otherwise masked by bulk averages. This allows researchers to understand not just whether a formulation works, but which particles within that formulation are responsible for efficacy, stability, and unwanted effects. For the nanomedicine and nanoparticle community, this capability has concrete strategic value. Single‑particle readouts enable more rigorous candidate selection, earlier elimination of unstable or poorly loaded formulations, and the identification of particle‑level features that correlate with in vitro and in vivo performance. These insights can then be translated into mechanistic quality attributes, supporting Quality‑by‑Design approaches, more informative specifications, and more robust, scalable manufacturing processes for advanced modalities such as mRNA‑LNPs, polymer nanoparticles and other complex nanomedicines.

VISIT WEBSITE

Anemocyte

Anemocyte is a leading Italian Biotech Manufacturing Organization (BMO) with over 25 years of highly specialized experience in Cell and Gene Therapies (CGTs). Specializing in plasmid DNA (pDNA) and messenger RNA (mRNA) development, Anemocyte addresses the evolving demands of the advanced therapies market. The company’s key differentiator is AMCAP™, a proprietary, patent-pending, “one-pot” technology that streamlines mRNA production by merging transcription and capping into a single, seamless reaction. This revolutionary platform drastically reduces processing times and batch costs while enhancing mRNA efficacy, flexibility, and scalability, positioning Anemocyte at the forefront of clinical and commercial-scale cell and gene therapy manufacturing.

VISIT WEBSITE

IRUBIS

IRUBIS develops advanced Process Analytical Technology (PAT) tool based on mid-infrared (MIR) spectroscopy to bring intelligence to biopharmaceutical manufacturing. Its flagship product, Monipa, uses MIR spectroscopy to quantify mRNA concentration, NTP consumption and reaction kinetics in real time during in vitro transcription. No sample prep or process-specific calibration is needed. Monipa can be coupled with an Autosampler for small-scale screening, an IVT vessel for bench-scale monitoring, or single-use flow cells for manufacturing-scale applications.

VISIT WEBSITE


register now

FormuTech summit

14 – 15 October, 2026 | Hotel Eurostars Universal, Lisbon, Portugal

Industry Package

1,995€

  • 2-Days Full Access
  • Coffee-Breaks & Lunch
  • Doc. Package
  • e-Poster Submission
Register now

mRNA Process Development & Manufacturing | LNP Formulations

© 2017 Copyright All Rights Reserved | Powered by EPM Group

Terms & Conditions | Privacy Policy